Stifel Financial Corp Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stifel Financial Corp lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,768 shares of the biopharmaceutical company's stock after purchasing an additional 13,647 shares during the period. Stifel Financial Corp's holdings in Halozyme Therapeutics were worth $1,471,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $69,000. Shaker Investments LLC OH increased its holdings in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after purchasing an additional 8,249 shares during the period. Foster & Motley Inc. raised its position in shares of Halozyme Therapeutics by 118.6% in the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock valued at $1,113,000 after buying an additional 12,630 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $731,000. Finally, Koa Wealth Management LLC grew its position in Halozyme Therapeutics by 10.6% during the fourth quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company's stock worth $3,940,000 after buying an additional 7,924 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 2.6%

HALO stock traded down $1.70 during trading on Monday, hitting $64.18. The company had a trading volume of 417,913 shares, compared to its average volume of 1,496,248. The stock has a market cap of $7.91 billion, a PE ratio of 18.96, a PEG ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business has a 50-day moving average of $61.45 and a 200-day moving average of $55.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.79 earnings per share. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. The trade was a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares of the company's stock, valued at $1,972,629.59. This trade represents a 12.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock valued at $1,276,552 over the last ninety days. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on HALO. JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.